We are live on ! Find out more

Praxis Precision Medicines

PRAX

Market cap $7.75B

277.62 USD

+15.03

5.72%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

279.00

+1.38

0.5%

1 day

5.72%

5 days

-3.02%

1 month

-0.9%

3 months

-25%

6 months

-17.88%

Year to date

-3.07%

1 year

61.08%

5 years

-16.4%

10 years

-33.42%

About: Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Employees: 10,998

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on November 2, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 23,219 shares of its common stock to fifty-nine new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report financial results for the third quarter ended September 30, 2026, before the financial markets open on Monday, November 9, 2026. The Company also announced details of its upcoming Investor Day and participation in November investor conferences.

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on October 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,478 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)

Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, underserved CNS markets with combined peak sales potential exceeding $15 billion. PRAX's $1.4 billion cash position supports a commercial buildout and reduces near-term capital market risk, with further upside from potential out-licensing and priority review vouchers.

Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Praxis: Commercial Launch Could Smash Expectations (Video)

Prax is analyzed using a sum-of-parts valuation approach, focusing on its lead asset, Ulixa. Recent updates from the Goldman Sachs presentation highlight key developments ahead of Ulixa's commercial launch. I assess PRAX's strategic positioning and upcoming catalysts tied to Ulixa's market entry.

Praxis: Commercial Launch Could Smash Expectations (Video)

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

Praxis Precision Medicines Q2 Earnings Call Highlights

Praxis Precision Medicines NASDAQ: PRAX said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, or DEEs, as both new drug applications remain under FDA review.

Praxis Precision Medicines Q2 Earnings Call Highlights

Stock Picks From Seeking Alpha's July 2026 New Analysts

Seeking Alpha welcomed 33 new analysts in July 2026. This article showcases their top picks and investment strategies. Highlighted companies include SELLAS Life Sciences, Chevron, B2Gold, Amazon, and QXO, each with detailed investment theses. Analysts emphasize asymmetric opportunities, event-driven catalysts, balance sheet strength, market structure, and sector-specific growth or risk factors.

Stock Picks From Seeking Alpha's July 2026 New Analysts

See News Rankings

Price charts implemented using Lightweight Charts™